-

10:59:13 PM

GLSI Stock News

GLSI - Greenwich LifeSciences Inc

12/29/22 6:48 AM

Nasdaq : GLSI

low float

Greenwich LifeSciences Provides Year End Update

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following year end update. At the 2022 San Antonio Breast Cancer Symposium, the Company met with the Flamingo-01...

RHEA-AI

very positive

12/01/22 6:00 AM

Nasdaq : GLSI

low float

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company’ s directors, officers, and...

RHEA-AI

neutral

08/11/22 10:30 AM

Nasdaq : GLSI

clinical triallow float

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following:. CEO Snehal Patel commented,“ We are thrilled to begin what we hope will be a successful reproduction of our...

RHEA-AI

neutral

08/03/22 8:00 AM

Nasdaq : GLSI

clinical triallow float

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following:. We continue to actively recruit and prepare additional US clinical sites. The Company is continuing to...

RHEA-AI

neutral

07/28/22 6:00 AM

Nasdaq : GLSI

low float

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following:. We believe that the Company is well capitalized with cash balance reported on the Company’ s Form 10- Q for...

RHEA-AI

neutral

07/12/22 6:00 AM

Nasdaq : GLSI

clinical triallow float

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that the Food and Drug Administration has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed. Company Contact Snehal Patel Investor Relations Office: 819-3232 Email:...

RHEA-AI

neutral

07/11/22 4:15 PM

Nasdaq : GLSI

buybacklow float

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that its Board of Directors has suspended the Company’ s previously announced share repurchase program. Company Contact Snehal Patel Investor Relations Office: 819-3232 Email: info@greenwichlifesciences.com.

RHEA-AI

neutral

05/23/22 7:00 AM

Nasdaq : GLSI

buybacklow float

Greenwich LifeSciences to Resume Stock Repurchase Program

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced today it would resume its existing Stock Repurchase Program. Under the repurchase program previously authorized by the board of directors, Greenwich LifeSciences may repurchase its outstanding shares of common stock from time to...

RHEA-AI

neutral

05/23/22 6:00 AM

Nasdaq : GLSI

clinical triallow float

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following:. We have completed the manufacturing of GP2, released 3 clinical lots, and started the stability testing...

RHEA-AI

neutral

04/20/22 6:10 AM

Nasdaq : GLSI

conferenceslow float

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Snehal Patel, CEO of Greenwich LifeSciences, will participate in the following upcoming investor, partnering, and...

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

GLSI Data

IndustryPharmaceutical Preparation Manufacturing
Websitegreenwichlifesciences.com
Security nameGreenwich LifeSciences Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees5
Tags
- Health Technology
- Biotechnology

About Greenwich LifeSciences Inc

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.